Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

Nicole Lamanna; Marco Montilo; Árpád Illés; Gabriel Etienne; Julio Delgado; Bryone Kuss; Constantine Tam; Fritz Offner; Francesco Bosch; Matthew S. Davids; Ulrich Jager; Paolo Ghia; Florence Cymalista; David T. Weaver; Stephanie Lustgarten; Hagop Youssoufian; Stephan Stilgenbauer; Ian W. Flinn

doi:10.1002/ajh.25639

Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

Nicole Lamanna, Marco Montilo, Árpád Illés, Gabriel Etienne, Julio Delgado, Bryone Kuss, Constantine Tam, Fritz Offner, Francesco Bosch, Matthew S. Davids, Ulrich Jager, Paolo Ghia, Florence Cymalista, David T. Weaver, Stephanie Lustgarten, Hagop Youssoufian, Stephan Stilgenbauer, Ian W. Flinn

College of Medicine and Public Health

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Duvelisib, a first-in-class oral dual PI3K-, inhibitor, was approved by the FDA for treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) after 2 prior therapies. In the phase 3 DUO trial, duvelisib 25 mg twice daily (BID) significantly improved efficacy vs ofatumumab (median progression-free survival [PFS], 13.3 vs 9.9 months; HR, 0.52 [P < .0001]; overall response rate, 74% vs 45% [P < .0001]) in patients with R/R CLL/SLL.1 Treatment-emergent adverse events (TEAEs) of special interest (AESI), such as infections, diarrhea, colitis, neutropenia, cutaneous reactions, ALT/AST elevation, and pneumonitis, were moderate and manageable with early intervention and dose modification.

Original language	English
Pages (from-to)	S20-S21
Number of pages	2
Journal	American Journal of Hematology
Volume	94
Issue number	S2
DOIs	https://doi.org/10.1002/ajh.25639
Publication status	Published - Nov 2019
Event	2019 Lymphoma and Myeloma Congress - Sheraton New York Times Square Hotel, New York, United States Duration: 23 Oct 2019 → 26 Oct 2019

Keywords

Duvelisib
relapsed CLL/SLL
refractory CLL/SLL
PI3K
lymphoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ajh.25639Licence: In Copyright

Cite this

Lamanna, N., Montilo, M., Illés, Á., Etienne, G., Delgado, J., Kuss, B., Tam, C., Offner, F., Bosch, F., Davids, M. S., Jager, U., Ghia, P., Cymalista, F., Weaver, D. T., Lustgarten, S., Youssoufian, H., Stilgenbauer, S., & Flinn, I. W. (2019). Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial. American Journal of Hematology, 94(S2), S20-S21. https://doi.org/10.1002/ajh.25639

@article{efd01b71feb742d3abb50bbb027c1afb,

title = "Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial",

abstract = "Duvelisib, a first-in-class oral dual PI3K-, inhibitor, was approved by the FDA for treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) after 2 prior therapies. In the phase 3 DUO trial, duvelisib 25 mg twice daily (BID) significantly improved efficacy vs ofatumumab (median progression-free survival [PFS], 13.3 vs 9.9 months; HR, 0.52 [P < .0001]; overall response rate, 74% vs 45% [P < .0001]) in patients with R/R CLL/SLL.1 Treatment-emergent adverse events (TEAEs) of special interest (AESI), such as infections, diarrhea, colitis, neutropenia, cutaneous reactions, ALT/AST elevation, and pneumonitis, were moderate and manageable with early intervention and dose modification. ",

keywords = "Duvelisib, relapsed CLL/SLL, refractory CLL/SLL, PI3K, lymphoma",

author = "Nicole Lamanna and Marco Montilo and {\'A}rp{\'a}d Ill{\'e}s and Gabriel Etienne and Julio Delgado and Bryone Kuss and Constantine Tam and Fritz Offner and Francesco Bosch and Davids, {Matthew S.} and Ulrich Jager and Paolo Ghia and Florence Cymalista and Weaver, {David T.} and Stephanie Lustgarten and Hagop Youssoufian and Stephan Stilgenbauer and Flinn, {Ian W.}",

year = "2019",

month = nov,

doi = "10.1002/ajh.25639",

language = "English",

volume = "94",

pages = "S20--S21",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley & Sons, Inc",

number = "S2",

note = "2019 Lymphoma and Myeloma Congress ; Conference date: 23-10-2019 Through 26-10-2019",

}

Lamanna, N, Montilo, M, Illés, Á, Etienne, G, Delgado, J, Kuss, B, Tam, C, Offner, F, Bosch, F, Davids, MS, Jager, U, Ghia, P, Cymalista, F, Weaver, DT, Lustgarten, S, Youssoufian, H, Stilgenbauer, S & Flinn, IW 2019, 'Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial', American Journal of Hematology, vol. 94, no. S2, pp. S20-S21. https://doi.org/10.1002/ajh.25639

Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial. / Lamanna, Nicole; Montilo, Marco; Illés, Árpád et al.
In: American Journal of Hematology, Vol. 94, No. S2, 11.2019, p. S20-S21.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

AU - Lamanna, Nicole

AU - Montilo, Marco

AU - Illés, Árpád

AU - Etienne, Gabriel

AU - Delgado, Julio

AU - Kuss, Bryone

AU - Tam, Constantine

AU - Offner, Fritz

AU - Bosch, Francesco

AU - Davids, Matthew S.

AU - Jager, Ulrich

AU - Ghia, Paolo

AU - Cymalista, Florence

AU - Weaver, David T.

AU - Lustgarten, Stephanie

AU - Youssoufian, Hagop

AU - Stilgenbauer, Stephan

AU - Flinn, Ian W.

PY - 2019/11

Y1 - 2019/11

N2 - Duvelisib, a first-in-class oral dual PI3K-, inhibitor, was approved by the FDA for treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) after 2 prior therapies. In the phase 3 DUO trial, duvelisib 25 mg twice daily (BID) significantly improved efficacy vs ofatumumab (median progression-free survival [PFS], 13.3 vs 9.9 months; HR, 0.52 [P < .0001]; overall response rate, 74% vs 45% [P < .0001]) in patients with R/R CLL/SLL.1 Treatment-emergent adverse events (TEAEs) of special interest (AESI), such as infections, diarrhea, colitis, neutropenia, cutaneous reactions, ALT/AST elevation, and pneumonitis, were moderate and manageable with early intervention and dose modification.

AB - Duvelisib, a first-in-class oral dual PI3K-, inhibitor, was approved by the FDA for treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) after 2 prior therapies. In the phase 3 DUO trial, duvelisib 25 mg twice daily (BID) significantly improved efficacy vs ofatumumab (median progression-free survival [PFS], 13.3 vs 9.9 months; HR, 0.52 [P < .0001]; overall response rate, 74% vs 45% [P < .0001]) in patients with R/R CLL/SLL.1 Treatment-emergent adverse events (TEAEs) of special interest (AESI), such as infections, diarrhea, colitis, neutropenia, cutaneous reactions, ALT/AST elevation, and pneumonitis, were moderate and manageable with early intervention and dose modification.

KW - Duvelisib

KW - relapsed CLL/SLL

KW - refractory CLL/SLL

KW - PI3K

KW - lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85073438461&partnerID=8YFLogxK

U2 - 10.1002/ajh.25639

DO - 10.1002/ajh.25639

M3 - Meeting Abstract

SN - 0361-8609

VL - 94

SP - S20-S21

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - S2

T2 - 2019 Lymphoma and Myeloma Congress

Y2 - 23 October 2019 through 26 October 2019

ER -

Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this